Cargando…

Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

INTRODUCTION: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), approved for the treatment of type 2 diabetes mellitus (T2DM). There currently exists no comparative data to support the use of alogliptin in combination with metfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kay, Stephen, Strickson, Amanda, Puelles, Jorge, Selby, Ross, Benson, Eugene, Tolley, Keith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380505/ https://www.ncbi.nlm.nih.gov/pubmed/28275958 http://dx.doi.org/10.1007/s13300-017-0245-8

Ejemplares similares

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea
por: Kang, Yu Mi, et al.
Publicado: (2019)

Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy
por: Gordon, Jason P., et al.
Publicado: (2015)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Effects of metformin and alogliptin on body composition in people with type 2 diabetes
por: Takeshita, Yumie, et al.
Publicado: (2018)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: Introduction of a spirocyclic moiety on the piperidine ring
por: Kodimuthali, Arumugam, et al.
Publicado: (2010)

Immunohistochemical Localization of Alogliptin, a DPP-4 Inhibitor, in Tissues of Normal and Type 2 Diabetes Model Rat
por: Yamamoto, Yutaro, et al.
Publicado: (2022)

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
por: Seino, Yutaka, et al.
Publicado: (2012)

DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin–sulfonylurea dual therapy with inadequate control
por: Wong, Carlos K H, et al.
Publicado: (2020)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
por: Toomey, Paul, et al.
Publicado: (2017)

Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study
por: Mamza, Jil, et al.
Publicado: (2015)

Efficacy and safety of fixed‐dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial
por: Ji, Linong, et al.
Publicado: (2017)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
por: Kimura, Tomomi, et al.
Publicado: (2012)

Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
por: Wang, Fei, et al.
Publicado: (2017)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis
por: Bodmer, Michael, et al.
Publicado: (2008)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy
por: Tai, He, et al.
Publicado: (2016)

Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy: Erratum
Publicado: (2016)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting
por: Strain, W. David, et al.
Publicado: (2019)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum
Publicado: (2017)

The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
por: Boddepalli, Chinmayi Sree, et al.
Publicado: (2022)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Circulating selenoprotein P levels predict glucose‐lowering and insulinotropic effects of metformin, but not alogliptin: A post‐hoc analysis
por: Takeshita, Yumie, et al.
Publicado: (2022)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial
por: Schernthaner, Guntram, et al.
Publicado: (2013)

Alogliptin benzoate for management of type 2 diabetes
por: Saisho, Yoshifumi
Publicado: (2015)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Improvements in Glycemic Control in Type 2 Diabetes Patients Switched From Sulfonylurea Coadministered With Metformin to Glyburide-Metformin Tablets
por: Duckworth, Wiliam
Publicado: (2003)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas
por: Chu, Patricia Y., et al.
Publicado: (2020)

Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
por: Baker, Matthew C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jf5b0p7u7m2lvjgr60ajq2o8p3